<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82313">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923948</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2013-001-09</org_study_id>
    <nct_id>NCT01923948</nct_id>
  </id_info>
  <brief_title>Preoperative Pain Control in Liver Surgery Patients</brief_title>
  <official_title>A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 150 mg Will Improve Pain Control in Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregabalin 150mg or placebo are administered 1 hour preoperatively in patients undergoing
      partial hepatectomy. Postoperatively, patients receive morphine as rescue analgesic.
      Morphine consumption in the first 48 hours is documented. Postoperative pain is measured by
      the visual analogue scale (VAS) score.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: In this Randomized Controlled Trial, patients undergoing partial hepatectomy will
      be administered a single pre-operative dose of Pregabalin or a placebo. Primary endpoints
      are as follows:

        -  Post-operative analgesic requirements

        -  Post-operative VAS scale (rated 0-10)

        -  Complications

        -  Post-operative antiemetic requirement

        -  Length of stay
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postoperative Opioid Consumption</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain Scores on the Visual Analog Scale</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, 150 mg pre-operative oral dose of Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single, placebo pre-operative dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>One 150 mg oral dose of Pregabalin given before surgery</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Pregabalin)</intervention_name>
    <description>One oral dose of placebo given before surgery</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Sugar pill manufactured to mimic Pregabalin 150 mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing partial hepatectomy

        Exclusion Criteria:

          -  contraindication against pregabalin

          -  creatinine &gt; 2.0 mg/dl

          -  GGT &gt;165, AST &gt;105, ALT &gt;135

          -  peptic Ulcus

          -  haemorrhagic diathesis

          -  angina pectoris, myocardial infarction

          -  stroke

          -  bronchial asthma

          -  opioid abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li ai jun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yin lei, MD</last_name>
    <phone>0086-021-81875534</phone>
    <email>yinlei409@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>li ai jun, MD</last_name>
    <phone>0086-021-81875531</phone>
    <email>ajli62@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yin lei, MD</last_name>
      <phone>0086-021-81875534</phone>
      <email>yinlei409@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>li ai jun, MD</last_name>
      <phone>0086-021-81875531</phone>
      <email>ajli62@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>yin lei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>vice president of the Eastern Hepatobiliary Surgery Hospital</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>randomized controlled trials(RCTs)</keyword>
  <keyword>Postoperative Pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
